Methylphenidate and Physical Activity in Reducing Cancer-Related Fatigue in Participants With Metastatic Melanoma Who Receive Anti-PD1 Immunotherapy

Inclusion Criteria:

1. Part 1: have a diagnosis of metastatic melanoma and previously received anti-PD1
immunotherapy provided that they received therapy at least 1 month prior to enrollment

2. Part 1: be aged 18 years or older

3. Part 1: be willing to engage in follow-up telephone calls with a research staff

4. Part 1: have telephone access so they can be contacted by the research staff

5. Part 1: have a hemoglobin level of >/= 8 g/dL within 2 weeks of enrollment*

6. Part 1: be able to understand the description of the study and give written informed
consent

7. Part 1: able to read, write and speak English.

8. Part 2: presence of fatigue as defined FACIT-F subscale of [in which 52 = no fatigue and 0 =worst possible fatigue]

9. Part 2: not currently taking Methylphenidate, or have taken it within the previous 10
days;

10. Part 2: able to complete the baseline assessment forms

11. Part 2: able to understand the recommendations for participation in the study

Exclusion Criteria:

1. Part 1: patients will be excluded if (1) have clinical evidence of cognitive failure
as evidenced by Memorial Delirium Assessment Scale score of >/=13 at baseline

2. Part 2: have a major contraindication to MP (e.g., allergy/hypersensitivity to study
medications or their constituents), or conditions making adherence difficult as
determined by the attending physician

3. Part 2: on monoamine oxidase inhibitors, or clonidine

4. Part 2: history of glaucoma

5. Part 2: history of have severe cardiac disease (New York Heart Association functional
class III or IV)

6. Part 2: tachycardia and/or uncontrolled hypertension

7. Part 2: currently receiving anticoagulants, anticonvulsants (phenobarbital,
diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine,
clomipramine, or desipramine)

8. Part 2: patients with CAGE-AID >/=2